Ignacio Melero, MD
Clinica Universidad de Navarra
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ignacio Melero, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:25 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05385705 · A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020Vall d'Hebron Institute of Oncology · terminated · Breast Neoplasms · principal investigator
- Ph2NCT02550249 · Neoadjuvant Nivolumab in GlioblastomaClinica Universidad de Navarra, Universidad de Navarra · completed · Glioblastoma Multiforme · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:25 UTC. The ranking covers the 200 most relevant of 44 PubMed records, and a shared surname and initials can bring in a namesake. All 44 on PubMed
- 2,672 citationsRCR 86.7
- 2,392 citationsRCR 180.8
- Palbociclib and Letrozole in Advanced Breast Cancer.N Engl J Med · 20162,383 citationsRCR 75.8
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.N Engl J Med · 20181,734 citationsRCR 58.5
- 1,071 citationsRCR 71.6
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.N Engl J Med · 20221,024 citationsRCR 73.8
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.Lancet Oncol · 2018834 citationsRCR 27.8
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.N Engl J Med · 2019780 citationsRCR 28.5
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.N Engl J Med · 2020673 citationsRCR 28.4
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Lancet Oncol · 2020426 citationsRCR 15.2